Neuphoria Therapeutics (NEUP) Price & Analysis

Compare

265 Followers

NEUP Stock Chart & Stats

$15.40

-$0.37(-10.36%)

At close: Jan 08 4:00 PM EST

$15.40

-$0.37(-10.36%)

Day’s Range― - ―

52-Week Range$2.11 - $21.40

Previous CloseN/A

Volume31.57K

Average Volume (3M)89.21K

Market Cap

$36.59M

Enterprise ValueN/A

Total Cash (Recent Filing)$17.05M

Total Debt (Recent Filing)$172.46K

Price to Earnings (P/E)―

Beta1.78

Next Earnings

Feb 20, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding2,357,613

10 Day Avg. Volume91,705

30 Day Avg. Volume89,214

Financial Highlights & Ratios

PEG Ratio-0.24

Price to Book (P/B)0.61

Price to Sales (P/S)0.00

P/FCF Ratio149.20

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$19.43

Price Target Upside26.17% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe Phase 3 AFFIRM-1 readout is seen as a critical catalyst for the BNC210 program in social anxiety disorder.

Market PositionBNC210 is well-positioned as a novel, non-psychedelic anxiolytic with a favorable safety profile and significant market potential.

Strategic PartnershipsThe relationship with Merck around MK-1167 made progress with the start of a P2 trial in Alzheimer's disease, triggering a $15M milestone to Neuphoria.

Bears Say

Clinical Trial RisksIf primary is missed, likely pause program and shift focus to PTSD program.

Neuphoria Therapeutics News

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

TipRanks offers insight into the biggest stock market stories worth reading on Tuesday. ...

20m ago

Why Is Neuphoria Therapeutics Stock (NEUP) Down 65% Today?

Neuphoria Therapeutics stock fell hard on Tuesday after the company posted results from a Phase 3 clinical trial. ...

4h ago

NEUP

Morning Movers: General Motors and RTX higher following Q3 reports

Stock futures hovered near record highs, though upside momentum has been muted in early trading as investors weigh...

4h ago

Neuphoria Therapeutics downgraded to Neutral from Buy at Lucid Capital

Lucid Capital analyst Elemer Piros downgraded Neuphoria Therapeutics (NEUP) to Neutral from Buy with a price target of...

7h ago

NEUP

Closing Bell Movers: DocGo soars after SteadyMD deal

Stock futures were broadly but marginally higher following sharp regular session gains, as markets exuded a cautiously optimistic...

18h ago

CCK

FLR

Neuphoria Therapeutics Inc trading resumes

17:00 EDT Neuphoria Therapeutics (NEUP) Inc trading resumes Published first on TheFly – the ultimate source for real-time,...

20h ago

NEUP

Neuphoria AFFIRM-1 trial misses primary endpoint, to discontinue SAD program

Neuphoria Therapeutics (NEUP) announced that the AFFIRM-1 Phase 3 trial of BNC210 for the acute treatment of social...

20h ago

NEUP

Neuphoria Therapeutics Inc trading halted, news pending

16:10 EDT Neuphoria Therapeutics (NEUP) Inc trading halted, news pending Published first on TheFly – the ultimate source...

21h ago

NEUP

H.C. Wainwright biotech analysts hold an analyst/industry conference call

Biotech Analysts, along with Dr. Murray Stein, Professor at the University of California, discuss Neuphoria’s near-term Phase 3...

15d ago

NEUP

Neuphoria Therapeutics Ends SAD Program After Trial Failure

Neuphoria Therapeutics ( ($NEUP) ) has issued an announcement. On October 20, 2025, Neuphoria Therapeutics announced that its...

19h ago

NEUP

Neuphoria Therapeutics: Strong Cash Position and Promising Pipeline Drive Buy Rating

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Neuphoria Therapeutics. The associated price target...

20d ago

NEUP

Neuphoria Therapeutics price target raised to $35 from $18 at Maxim

Maxim raised the firm’s price target on Neuphoria Therapeutics (NEUP) to $35 from $18 and keeps a Buy...

1M ago

NEUP

Neuphoria Therapeutics completes target enrollment in Phase 3 AFFIRM-1 trial

Neuphoria Therapeutics (NEUP) announced the achievement of target enrollment of 332 participants in the AFFIRM-1 Phase 3 trial...

2M ago

NEUP

Neuphoria Therapeutics initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of Neuphoria Therapeutics (NEUP) with a Buy rating and $81 price target The company...

2M ago

NEUP

NEUP FAQ

What was Neuphoria Therapeutics’s price range in the past 12 months?

Neuphoria Therapeutics lowest stock price was $2.11 and its highest was $21.40 in the past 12 months.

What is Neuphoria Therapeutics’s market cap?

Neuphoria Therapeutics’s market cap is $36.59M.

When is Neuphoria Therapeutics’s upcoming earnings report date?

Neuphoria Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is 243 days ago.

How were Neuphoria Therapeutics’s earnings last quarter?

Currently, no data Available

Is Neuphoria Therapeutics overvalued?

According to Wall Street analysts Neuphoria Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Neuphoria Therapeutics pay dividends?

Neuphoria Therapeutics does not currently pay dividends.

What is Neuphoria Therapeutics’s EPS estimate?

Neuphoria Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Neuphoria Therapeutics have?

Neuphoria Therapeutics has 2,357,613 shares outstanding.

What happened to Neuphoria Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Neuphoria Therapeutics?

Currently, no hedge funds are holding shares in NEUP

Neuphoria Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-59.91%

Trailing 12-Months

Asset Growth

-33.77%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

NEUP Stock 12 Month Forecast

Average Price Target

$19.43

▲(26.17% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","48":"$48","12.75":"$12.75","24.5":"$24.5","36.25":"$36.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,12.75,24.5,36.25,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Jan<br/>2024","9":"Jul<br/>2024","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.95,13.723076923076922,15.496153846153845,17.26923076923077,19.04230769230769,20.815384615384616,22.588461538461537,24.361538461538462,26.134615384615387,27.907692307692308,29.680769230769233,31.453846153846154,33.22692307692308,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.95,12.525384615384615,13.100769230769231,13.676153846153845,14.25153846153846,14.826923076923077,15.40230769230769,15.977692307692307,16.553076923076922,17.128461538461536,17.703846153846154,18.279230769230768,18.854615384615386,{"y":19.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.95,11.207692307692307,10.465384615384615,9.723076923076922,8.98076923076923,8.238461538461538,7.496153846153846,6.753846153846154,6.0115384615384615,5.269230769230769,4.526923076923077,3.7846153846153854,3.042307692307693,{"y":2.3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34.62,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.4,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.28,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.64,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.28,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.8,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.2,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.28,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.08,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.28,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >